[Clinical effects of human lymphoblastoid interferon in patients with hematologic neoplasms].


Sixteen patients with hematologic neoplasms were treated with Human Lymphoblastoid Interferon (HL-BI) derived from Namalwa cell line. They were 6 multiple myeloma, 8 acute leukemia and 2 malignant lymphoma patients. All patients were previously treated with anticancer agents except one case with multiple myeloma. HLBI, 3.0 X 10(6) IU/day, was daily… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.